205 related articles for article (PubMed ID: 31325903)
21. Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma.
Gramatzki D; Kickingereder P; Hentschel B; Felsberg J; Herrlinger U; Schackert G; Tonn JC; Westphal M; Sabel M; Schlegel U; Wick W; Pietsch T; Reifenberger G; Loeffler M; Bendszus M; Weller M
Neurology; 2017 Apr; 88(15):1422-1430. PubMed ID: 28298550
[TBL] [Abstract][Full Text] [Related]
22. Clinical and Genetic Factors Associated With Severe Hematological Toxicity in Glioblastoma Patients During Radiation Plus Temozolomide Treatment: A Prospective Study.
Lombardi G; Rumiato E; Bertorelle R; Saggioro D; Farina P; Della Puppa A; Zustovich F; Berti F; Sacchetto V; Marcato R; Amadori A; Zagonel V
Am J Clin Oncol; 2015 Oct; 38(5):514-9. PubMed ID: 24064758
[TBL] [Abstract][Full Text] [Related]
23. Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial.
Malmström A; Poulsen HS; Grønberg BH; Stragliotto G; Hansen S; Asklund T; Holmlund B; Łysiak M; Dowsett J; Kristensen BW; Söderkvist P; Rosell J; Henriksson R;
Acta Oncol; 2017 Dec; 56(12):1776-1785. PubMed ID: 28675067
[TBL] [Abstract][Full Text] [Related]
24. Patterns of care and outcomes of chemoradiation versus radiation alone for MGMT promoter unmethylated glioblastoma.
Lee A; Malakhov N; Sheth N; Wang A; Han P; Schreiber D
Clin Neurol Neurosurg; 2018 Jul; 170():127-131. PubMed ID: 29777945
[TBL] [Abstract][Full Text] [Related]
25. Standard dose and dose-escalated radiation therapy are associated with favorable survival in select elderly patients with newly diagnosed glioblastoma.
Jackson WC; Tsien CI; Junck L; Leung D; Hervey-Jumper S; Orringer D; Heth J; Wahl DR; Spratt DE; Cao Y; Lawrence TS; Kim MM
J Neurooncol; 2018 May; 138(1):155-162. PubMed ID: 29388034
[TBL] [Abstract][Full Text] [Related]
26. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
Li H; Li J; Cheng G; Zhang J; Li X
Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
[TBL] [Abstract][Full Text] [Related]
27. Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide.
Weiler M; Hartmann C; Wiewrodt D; Herrlinger U; Gorlia T; Bähr O; Meyermann R; Bamberg M; Tatagiba M; von Deimling A; Weller M; Wick W
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):670-6. PubMed ID: 19836157
[TBL] [Abstract][Full Text] [Related]
28. Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide.
Minniti G; Amelio D; Amichetti M; Salvati M; Muni R; Bozzao A; Lanzetta G; Scarpino S; Arcella A; Enrici RM
Radiother Oncol; 2010 Dec; 97(3):377-81. PubMed ID: 20855119
[TBL] [Abstract][Full Text] [Related]
29. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.
Hegi ME; Diserens AC; Godard S; Dietrich PY; Regli L; Ostermann S; Otten P; Van Melle G; de Tribolet N; Stupp R
Clin Cancer Res; 2004 Mar; 10(6):1871-4. PubMed ID: 15041700
[TBL] [Abstract][Full Text] [Related]
30. Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status.
Brandes AA; Tosoni A; Franceschi E; Sotti G; Frezza G; Amistà P; Morandi L; Spagnolli F; Ermani M
J Clin Oncol; 2009 Mar; 27(8):1275-9. PubMed ID: 19188675
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide.
Younis SG; Khedr RA; El-Shorbagy SH
J Egypt Natl Canc Inst; 2016 Mar; 28(1):23-30. PubMed ID: 26682634
[TBL] [Abstract][Full Text] [Related]
32. Is MGMT promoter methylation to be considered in the decision making for recurrent surgery in glioblastoma patients?
Pala A; Schmitz AL; Knoll A; Schneider M; Hlavac M; König R; Wirtz CR; Coburger J
Clin Neurol Neurosurg; 2018 Apr; 167():6-10. PubMed ID: 29425743
[TBL] [Abstract][Full Text] [Related]
33. Survival Outcomes of Elderly Patients With Glioblastoma Multiforme in Their 75th Year or Older Treated With Adjuvant Therapy.
Harris G; Jayamanne D; Wheeler H; Gzell C; Kastelan M; Schembri G; Brazier D; Cook R; Parkinson J; Khasraw M; Louw S; Back M
Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):802-810. PubMed ID: 28602411
[TBL] [Abstract][Full Text] [Related]
34. MGMT promoter methylation in patients with glioblastoma: is methylation-sensitive high-resolution melting superior to methylation-sensitive polymerase chain reaction assay?
Yamashita S; Yokogami K; Matsumoto F; Saito K; Mizuguchi A; Ohta H; Takeshima H
J Neurosurg; 2018 May; 130(3):780-788. PubMed ID: 29726772
[TBL] [Abstract][Full Text] [Related]
35. Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide.
Thon N; Eigenbrod S; Grasbon-Frodl EM; Lutz J; Kreth S; Popperl G; Belka C; Kretzschmar HA; Tonn JC; Kreth FW
J Neurol Neurosurg Psychiatry; 2011 Apr; 82(4):441-6. PubMed ID: 20861061
[TBL] [Abstract][Full Text] [Related]
36. Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas.
Yin AA; He YL; Etcheverry A; Liu YH; Aubry M; Barnholtz-Sloan J; Liu BL; Mosser J; Lu ZF; Zhang X
Clin Epigenetics; 2019 May; 11(1):76. PubMed ID: 31088577
[TBL] [Abstract][Full Text] [Related]
37. Dose Escalated Radiation Therapy for Glioblastoma Multiforme: An International Systematic Review and Meta-Analysis of 22 Prospective Trials.
Singh R; Lehrer EJ; Wang M; Perlow HK; Zaorsky NG; Trifiletti DM; Bovi J; Navarria P; Scoccianti S; Gondi V; Brown PD; Palmer JD
Int J Radiat Oncol Biol Phys; 2021 Oct; 111(2):371-384. PubMed ID: 33991621
[TBL] [Abstract][Full Text] [Related]
38. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.
Kim BS; Kong DS; Seol HJ; Nam DH; Lee JI
J Neurooncol; 2017 Jul; 133(3):615-622. PubMed ID: 28536992
[TBL] [Abstract][Full Text] [Related]
39. Treatment options and outcomes for glioblastoma in the elderly patient.
Arvold ND; Reardon DA
Clin Interv Aging; 2014; 9():357-67. PubMed ID: 24591820
[TBL] [Abstract][Full Text] [Related]
40. Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients.
Yuan G; Niu L; Zhang Y; Wang X; Ma K; Yin H; Dai J; Zhou W; Pan Y
J Neurooncol; 2017 May; 133(1):193-201. PubMed ID: 28516344
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]